EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

The Antifibrotic Effects of Eplerenone in Hypertrophic Cardiomyopathy

Stavroula Papapostolou, Leah Iles, Jessica O'Brien, Sarah J Gutman, Andris Ellims, James Hare, Dion Stub, Stuart Moir, Andrew J Taylor

JACC: Heart Failure · 2025-07 · 13 (7) · 102415

DOI: 10.1016/j.jchf.2025.01.021 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Heart Failure, 2025-07. Verfasst von Stavroula Papapostolou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, The Alfred Hospital, Melbourne, Australia; Faculty of Medicine, Nursing and Health Sciences, Monash University…. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Mineralocorticoid Receptor Antagonists, Spironolactone, Myocardium. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: NHMRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Fibrosis plays a central role in hypertrophic cardiomyopathy (HCM), contributing to symptoms via impaired systolic and diastolic function and ventricular arrhythmias. OBJECTIVES: The aim of this study was to determine if eplerenone has an antifibrotic effect in nonobstructive HCM (resting left ventricular outflow tract gradient

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicMineralocorticoid Receptor AntagonistsSpironolactoneMyocardiumHumansEplerenoneMaleFemaleDouble-Blind MethodMiddle AgedFibrosisAdultTreatment OutcomeMagnetic Resonance Imaging, CineAgedDiastole

Stichwörter der Autor:innen

T1 mappingcardiac fibrosiscardiac magnetic resonancehypertrophic cardiomyopathy

Substanzen

EplerenoneMineralocorticoid Receptor AntagonistsSpironolactone

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, The Alfred Hospital, Melbourne, Australia; Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia; Department of Cardiology, Western Health, Melb…
  • Department of Cardiovascular Medicine, The Alfred Hospital, Melbourne, Australia; Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia.
  • Department of Cardiovascular Medicine, The Alfred Hospital, Melbourne, Australia; Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia; Baker Heart and Diabetes Institute, Melbourne,…
  • Department of Cardiovascular Medicine, The Alfred Hospital, Melbourne, Australia.
  • Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia; Monash Victorian Heart Institute, Melbourne, Australia.

Förderung

  • NHMRC

Zitieren

APA

Papapostolou, S., Iles, L., O'Brien, J., Gutman, S. J., Ellims, A., Hare, J., Stub, D., Moir, S., & Taylor, A. J. (2025). The Antifibrotic Effects of Eplerenone in Hypertrophic Cardiomyopathy. JACC: Heart Failure, 13(7), 102415. https://doi.org/10.1016/j.jchf.2025.01.021

Vancouver

Papapostolou S, Iles L, O'Brien J, Gutman SJ, Ellims A, Hare J, et al. The Antifibrotic Effects of Eplerenone in Hypertrophic Cardiomyopathy. JACC: Heart Failure. 2025;13(7):102415. doi:10.1016/j.jchf.2025.01.021

BibTeX
@article{Papapostolou2025,
  author = {Papapostolou, Stavroula and Iles, Leah and O'Brien, Jessica and Gutman, Sarah J and Ellims, Andris and Hare, James and Stub, Dion and Moir, Stuart and Taylor, Andrew J},
  title = {The Antifibrotic Effects of Eplerenone in Hypertrophic Cardiomyopathy},
  journal = {JACC: Heart Failure},
  year = {2025},
  volume = {13},
  number = {7},
  pages = {102415},
  doi = {10.1016/j.jchf.2025.01.021}
}
Kostenlos starten →